Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference
- Professor Gertsch identifies novel transport mechanism and presents new information on mode of action as part of presentation entitled ‘Identification of an Endocannabinoid Reuptake and Recycling Machinery’
- Presentation forms part of 10th Gordon Research Conference on ‘Cannabinoid Function in the CNS’ held 16-21 July 2023 outside Barcelona, Spain
BASEL, Switzerland – 18 July 2023 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that its co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, last night presented new findings on the endocannabinoid transporter at the 10th Gordon Research Conference on ‘Cannabinoid Function in the CNS – Charting the Course to Novel Therapeutics from a Fundamental Understanding of Cannabinoid Neurobiology’.
